Please assess the completion status of the following clinical trial:

Trial Title: Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly subjects (\> 64 years) with a diagnosis of primary insomnia.~Exclusion Criteria:~* History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) axis I disorder other than primary insomnia.~* Sleep apnea, or restless legs syndrome.~* Daytime napping of more than 1 hour per day.~* Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit.~* Unwillingness to refrain from drugs, over-the-counter or herbal medication having an effect on sleep or behavior.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABECD (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- BCADE (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- CDBEA (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- DECAB (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- EADBC (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- DCEBA (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- EDACB (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- AEBDC (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- BACED (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- CBDAE (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).